Universitätsklinikum Hamburg-Eppendorf (UKE)

Increased Cartilage Damage in Metacarpophalangeal Joints of ACPA Positive Rheumatoid Arthritis (RA) Patients Using T2 Mapping in 3 Tesla Magnetresonance Imaging (MRI) (2017) Renner N, Kleyer A, Simon D, Krönke G, Rech J, Schett G, Welsch G, Pachowsky M Conference contribution Fumaric Acid Esters: Patient Characteristics and Duration of Therapy from the PsoBest German Psoriasis Registry (2017) Augustin M, Reich K, Spehr C, Rustenbach SJ, Mrowietz U, Radtke MA, Wilsman-Theis D, et al. Conference contribution Fear of progression in patients with low-risk malignant melanoma (2017) Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, et al. Conference contribution Rheumatism and the spine (2017) Swoboda B, Ruether W Journal article Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment (2017) Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study (2017) Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study (2017) Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, et al. Conference contribution SOP-palliative sedation (2017) Oechsle K, Radbruch L, Wolf C, Ostgathe C Journal article Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study (2017) Mrowietz U, Augustin M, Thaci D, Reich K, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis with without previous Systemic Therapy for Improvement of Nail Symptoms: NAPSI Results PRIME Study (2017) Thaci D, Reich K, Mrowietz U, Augustin M, Kneidl J, Hentschke C, Simang M, et al. Conference contribution